Key result
Prophylactic antilymphoblast globulin linked to ~37-point higher 2-year graft survival in diabetic renal recipients.
Observational (n=48)
Answers are grounded in this paper and cite their sources.
The results of 54 renal transplants performed on 48 patients with end stage renal disease and insulin-dependent diabetes mellitus are reported. Pre-transplant screening with coronary angiography was done to determine the presence and severity of coronary artery disease and left ventricular dysfunction. There were 12 living related donor (group 1) and 42 cadaver renal transplants. The cadaver transplant recipients were grouped further into those who received additional prophylactic immunosuppression with antilymphoblast globulin (group 2, 18 patients) and those who received standard immunosuppression with azathioprine and prednisone (group 3, 18 patients). The 2-year patient and graft survival rates in groups 1 to 3 were 81 and 67, 88 and 69, and 61 and 32 per cent, respectively. The use of prophylactic antilymphoblast globulin for adjunctive immunosuppression resulted in significantly improved graft survival among cadaver recipients (p less than 0.003). Selection of patients for transplantation on the basis of preliminary screening with coronary angiography was found to have a major impact on patient survival.
No takes yet. Share an insight, caveat, or question.
Khauli et al. (1983) conducted an observational in End stage renal disease and insulin-dependent diabetes mellitus (n=48). Prophylactic antilymphoblast globulin (adjunctive immunosuppression) vs. Standard immunosuppression with azathioprine and prednisone was evaluated on 2-year graft survival among cadaver renal transplant recipients (p=<0.003). Prophylactic antilymphoblast globulin improved 2-year graft survival vs standard immunosuppression in diabetic cadaver renal recipients.
Synapse has enriched 10 related papers. Consider them for comparative context: